ClinicalTrials.gg
RecruitingNCT06367907BE-STUpdated Apr 16, 2024

Biological Effects of Schema Therapy

An interventional study of schema therapy in Personality Disorders, sponsored by Jena University Hospital. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-04-16.

Primary conditionBorderline Personality DisorderRegistry: Personality DisordersReclassifiedWhy we changed it
Registry
Personality Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Borderline Personality Disorder
Why
  1. The study's title name Borderline Personality Disorder, a narrower term within Personality Disorders.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jena University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 5 months after the study started (first participant enrolled Sep 2021, registered Mar 2024).
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Borderline Personality Disorder with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Borderline Personality Disorder · Germany.

Planned enrollment
14th of 28
120 · median 120
Started
2021
with 3 others
No phase
20 of 37
4 open now
Registered
30th of 37
by date

Among the 37 studies in Borderline Personality Disorder with a site in Germany, this one is the 14th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2021, is one of 20 with no phase, and was the 30th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

6 of the 37 studies in Borderline Personality Disorder with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Borderline Personality Disorder with a site in Germany, or all of them as a file.
02

Study summary

Background: The major aim of this study is to compare the effects of emotion focused (experiential) and cognitive interventions of schema therapy (ST) on emotion regulation deficits in patients with borderline personality disorder (BPD) according to DSM-V (alternative model) criteria. In a randomized, single-blinded parallel-group design clinical effects as well as effects on neurotransmitter metabolism and connectivity will be compared.

Method: While the 9-weeks treatment protocol of particular interest includes emotion focused interventions (ST-EF, n=60) such as chair dialogs, imagery rescripting or role play, the active control condition (ST-AC, n=60) is restricted to cognitive interventions, e.g. psychoeducation or pro/contra discussions. MEGA-PRESS 1H-MR spectroscopy and resting-state functional MR imaging (rs-fMRI) will be used before/after treatment protocols (T0-T1) and 6 months after the end of therapy (T2) to assess the effects on glutamate (Glx) and GABA metabolism in key regions of the target networks (executive control network, ECN: dorsolateral prefrontal cortex, DLPFC; salience network, SN: anteromedial cingulate cortex, aMCC; default mode network, DMN: pregenual cingulate cortex, pgACC) and to investigate the corresponding altered connectivity in these networks. The biological aberrations at T0 as compared to healthy controls (n=60) and treatment effects (at T1 and T2, n≥40 in each condition) on these aberrations will be linked to clinical effects measured by an extensive test battery with particular interest on emotion regulation, and specified by the Reliable Change Index (RCI). For longitudinal data mixed model analysis will be performed.

The main questions are (1) whether the emotion regulation deficit and the pattern of BPD-specific symptomatology are associated with a specific pattern of Glx and GABA concentrations in the DLPFC, aMCC and pgACC and corresponding deviations of functional connectivity within the ECN, SN and DMN. Hypothesis: Depending on primary and secondary outcome measures at T0, altered RSFC in the DMN, SN and ECN and corresponding altered Glx or GABA concentrations are assumed. (2) whether both treatment conditions have different clinical effects on the ability to regulate emotions and whether the respective clinical effects are associated with the changes in neurobiological aberrations. Hypothesis: It is hypothesized that the ST-EF condition will improve emotion regulation skills more effectively than the control condition. Only in the ST-EF condition are higher response and remission rates expected in the primary and secondary outcome measures, as well as effects on the ECN, SN and DMN with corresponding changes in RSFC and Glx or GABA concentrations.

Read the detailed description

2.3 Work program and proposed research methods

The work program is divided into the following three work packages:

  1. Recruitment of patients and healthy subjects including diagnostic and psychological assessments as well as assessment of clinical outcome.
  2. Collecting the MR-related (Glx, GABA, RSFC).
  3. Data evaluation and analysis of the results.

Recruitment of patients and healthy subjects Patients will be recruited from routine admissions to the psychiatric day-hospital. According to our power calculation, we aim to include at least 120 patients with BPD according to the general and borderline specific criteria of the alternative DSM-5 Model for Personality Disorders (Section III of DSM 5, p 761ff (APA, 2013), which includes a specific dimensional pattern of impairments in personality functioning and pathological personality traits for diagnosis.

A total of at least 60 healthy volunteers will be recruited by newspaper advertisement. They will be examined using a semi-structured interview and self-ratings (SCL-90-R) to assess current mental status, to exclude personal or first-degree family history of psychiatric disorders (including substance abuse) or history of neurological or major medical conditions that might affect brain function.

Description of therapy conditions with/without emotion focused schema therapy interventions:

Deficits in emotion regulation are widely seen as a core pathology in BPD. Hence, quicker and more intense emotional activation can a priori be expected in every BPD patient. This study makes use of the fact that some interventions in ST evoke intense emotions (child modes), e.g. to foster awareness of child's needs, while others aim to establish a "healthy distance" from overintense emotions to enable adequate parental care (healthy adult mode). With regard to emotions schema therapy techniques have been divided into therapy relationship, experiential, cognitive, and behavioral techniques (Fassbinder et al., 2016). Schem therapy assumes that by using these strategies, the patient's fear of emotions reduces while willingness to overcome experiential avoidance increases (Fassbinder et al., 2016). This approach also clarifies "old" (biographically linked) goals of emotion regulation behavior (now counting as dysfunctional or a strategies of emotional avoidance), now replacing them by "new" (actual) goals that require and enhance new (functional) emotion regulation behavior.

MR-based investigation protocol

Scheduled acquisitions (scan time including patient positioning up to 1.5h):

  • High-resolution, T1-weighted 3D whole brain scan using the MP-RAGE sequence TR/TE/TI = 2530/2.7/1100 ms; α = 7°; 176 sagittal slices of 1 mm thickness; FOVAP×HF = 256 × 256 mm²; in-plane matrix: 256 × 256 pixels; acquisition time: 6 min.
  • Resting state fMRI scan of the entire brain using T2*-weighted EPI; TR/TE = 2520/30 ms; whole brain coverage with 45 transverse slices (thickness 2.5 mm); FoVAP×LR = 220×210 mm²; in-plane matrix: 88×84 pixels; 240 volumes; TA = 10 min.
  • 1H-MR spectra with MEGA-PRESS sequence in three voxels placed in the aMCC (SN network) and left and right DLPFC (ECN network).

Manual adjustment of field homogeneity and water suppression (5 min); TR/TE = 2000/68 ms; 256 alternating single acquisitions with subsequent application of frequency-selective RF pulses at 1.9 ppm and 7.5 ppm, respectively; additional series acquisition of twelve water non-suppressed single scans with varying echo times (TR = 20 s, TE's = 30, 40, 50, 60, 75, 90, 110, 150, 175, 200, 250, 300 ms), TA = 17 min per voxel; total MRS duration of 50 - 55 min.

Photoplethysmogram (PPG) and respiration recordings during MRI acquisition with 500 Hz using an MR-compatible polygraph MP150 (BIOPAC Systems Inc., Goleta, CA, USA). Respiratory activity will be monitored by a strain gauge transducer incorporated in a belt tied around the chest, approximately at the level of the xiphoid process. The PPG sensor will be attached to the proximal phalanx of the left index finger.

Analysis of baseline (T0) MRI-data:

Separate analysis for rs-fMRI and 1H-MRS data:

A seed-based correlation analysis will be used to explore the whole-brain RSFC pattern of the regions being central to the study, i.e., the aMCC and DLPFC. Analysis of variance (ANOVA) will be applied to test for RSFC differences between patient groups and controls.

The same analyses will be applied to analyze group differences of the local Glx and GABA concentrations as well as the Glx/GABA balance in aMCC and DLPFC between patients and controls.

Associations between rs-fMRI and 1H-MRS data:

A linear mixed model analysis will be performed to investigate differences of associations between RSFC (SN and ECN) and Glx or GABA concentrations at the aMCC and DLPFC between patients and controls.

Follow-up (T0-T1;T1-T2) analysis of treatment effects on MRI target parameters (RSFC, Glx, GABA)

Separated analysis for rs-fMRI and 1H-MRS data:

Analysis of variance (ANOVA) for repeated measures will be applied to test for effects of group belonging (ST-EF, ST-AC, and healthy subjects; ST-EF vs. ST-AC) on changes of RSFC, Glx and GABA over time, as well as for within-subject changes between T0 and T1, and T1 and T2 scans.

Associations between RSFC and the local Glx and GABA concentrations:

A linear mixed model analysis will be performed to investigate changes after 9 weeks of treatment (T0 vs. T1) or 6month of catamnesis (T1 vs. T2) of either therapeutic condition (ST-EF, ST-AC) compared to unspecific changes over time in healthy controls as well as between treatment groups.

In a first step, this analysis will be performed separately in both treatment groups and healthy controls and for both neurotransmitters (Glx, GABA) and both spectroscopic and functional connectivity target regions (aMCC, DLPFC).

In the second (more important) step, potential treatment condition driven differences in the correlations between metabolic and RSFC parameters will be investigated by applying the same model including the factor treatment group.

Clinical outcome

Evaluation of changes of core symptoms and their clinical significance:

In a follow-up (T0-T1; T1-T2) analysis of treatment effects, the individual change of each patient in measures of the primary (Emotion Regulation Inventory, ERI) and secondary (Borderline Personality Disorder Severity Index - fourth version, BPDSI-IV; Levels of Personality Functioning Scale, SEFP; Personality Inventory for DSM-5 (Criterion B), PID-5; Borderline Symptom List (95 Items) BSL-95; Inventory of Interpersonal Problems, IIP-D; Young Schema Questionnaire (short version), YSQ-S3r, and Schema Mode Inventory (118 item version), SMI) outcome criteria will be estimated by the Reliable Change Index (RCI) (Wise, 2004) in each therapeutic condition.

Evaluation of changes in primary and secondary criteria and their clinical significance: In each therapeutic condition the improvement of each patient in measures of the primary (ERI) and secondary (BPDSI-IV, SEFP, PID-5, BSL-95, IIP-D, YSQ-S3r, and SMI) outcome criteria will be estimated by the Reliable Change Index (RCI), which summarizes changes at the level of an individual in the context of observed changes for the whole sample.

The RCI provides information about the functioning of an individual before/after therapy on an outcome measure, including the normative information about this measure by dividing the difference between pre- and post-treatment scores by the standard error (that includes also the reliability coefficient, not only the standard deviation of the measure). The change will be considered as being unlikely the product of measurement error (i.e., considered reliable), if the RCI is greater than 1.96. When the individual has a change score greater than 1.96 it can be assumed that the individual has improved. More detailed information on RCI scores and their meaning in each outcome measurement is given in the uploaded material.

Interrelation between clinical outcome parameters and neurobiological findings:

A linear mixed model analysis will be used that includes those MRI-data (RSFC, Glx, GABA) that have been significantly affected by therapy (T0 vs. T1) and those clinical scores that reached the highest RCI. The detected significant interactions will be compared between the ST-EF and ST-AC treatment condition.

03

Conditions studied

  • Personality Disorders

Browse trials for

Keywords

  • borderline personality disorder
  • emotion regulation
  • schema therapy
  • brain networks
04

In context

Borderline Personality Disorder Reclassified

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

This study's planned enrollment of 120 is above the median of 70 across 222 interventional studies indexed under Borderline Personality Disorder.

Browse Borderline Personality Disorder studies →

Lead sponsor

Jena University Hospital is the lead sponsor of 64 studies on the registry; 20 are open to participants now.

Compared within Borderline Personality Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Personality Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are eligible if they

    • fulfil diagnostic criteria (1.-4. see below) of BPD according to the Alternative Model (Sec-tion III of DSM 5, p 761ff (APA, 2013),
    • are between 18 and 30 years of age,
    • are female,
    • are right-handed,
    • are free of any treatment with antidepressants, antipsychotic or mood stabilizing medication (sporadic use of tranquillizers to induce sleep will be permitted)
    • have never been in psychotherapy before (in particular DBT, ST, CBT, TBP),
    • are willing to participate in (group) therapy,
    • are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if they

    • acutely suffer suicidal ideas,
    • suffer manifest affective or anxiety disorder ac-cording to criteria or have a lifetime his-tory of or current psychotic disorder (except brief psychotic disorder according to the DSM-5),
    • present a clinically manifest trauma-related dis-order (in particular PTSD),
    • suffer dissociative identity disorder, substance dependence needing clinical detoxification, ano-rexia nervosa with \< 14 or a serious and/or unstable medical illness,
    • have an IQ below 80,
    • are at any risk in terms of MRI investigations
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    ST-EF, schema therapy - emotion focused

    9-weeks treatment protocol based on emotion focused interventions, such as chair dialogs, imagery rescripting or role play

    Other: schema therapy

  • Active comparator
    ST-AC, schema therapy - active control

    9-weeks treatment protocol based on cognitive interventions, e.g. psychoeducation, socratic dialog, pro/contra discussions etc. but no experiential techniques

    Other: schema therapy

Interventions

  • Otherschema therapy

    In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.

07

What researchers measure

Primary outcomes

  1. Changes in emotion regulation capabilities

    Being the core issue of this study, changes in emotion regulation capabilities are defined as primary outcome and will be assessed by the Emotion Regulation Inventory (ERI), which follows the Process Model of Emotion Regulation proposed by James Gross. Evaluation of changes in primary and secondary criteria and their clinical significance: In each therapeutic condition the improvement of each patient in measures of the primary and secondary outcome criteria will be estimated by the Reliable Change Index (RCI)(1)((2), which summarizes changes at the level of an individual in the context of observed changes for the whole sample. More detailed information on RCI scores and their meaning in each outcome measurement is given in the uploaded material.

    Time frame: 9 weeks (T1), 6 month after end of therapy (T2)

Secondary outcomes

  1. Improvement of BPD specific symptomatology

    The change of BPD specific symptomatology as measured by the Borderline Personality Disorder Severity Index - fourth version (BPDSI-IV) was defined as a secondary outcome measure.

    Time frame: 9 weeks (T1), 6 month after end of therapy (T2)

  2. Change of personality traits

    The change in personality traits as measured by the Personality Inventory for DSM-5 (Criterion B) (PID-5) was defined as secondary outcome measure.

    Time frame: 9 weeks (T1), 6 month after end of therapy (T2)

  3. Changes of the intensity of early maladaptive schemas.

    The Young Schema Questionnaire (short version) (YSQ-S3r) will be used to measure therapy induced changes of the intensity of early maladaptive schemas.

    Time frame: 9 weeks (T1), 6 month after end of therapy (T2)

  4. Changes of the intensity of schema modes.

    The Schema Mode Inventory (118 item version) (SMI) will be used to measure therapy induced changes of schema modes.

    Time frame: 9 weeks (T1), 6 month after end of therapy (T2)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2024, 39 months after the start.

Of 106 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's planned 39 months is above that.

Counting every sponsor, half of 108 studies reached it within 35 months; a quarter within 24 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Apr 16, 2024
StartActual
Sep 9, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Jun 2025
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06367907
Lead sponsor
Jena University Hospital
Responsible party
Stefan Smesny (Prof. Dr. S. Smesny (MD, PhD), Jena University Hospital) — Principal investigator
First posted
Apr 16, 2024
Start date
Sep 9, 2021
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Apr 16, 2024

Study contacts

Stefan Smesny, PhD
Contact
stefan.smesny@med.uni-jena.de
+4936419390451
Stefan Smesny
principal investigator · Jena University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion